Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer

Published:2018-10-16 Issue:2 Volume:25 Page:652-662
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Vaishampayan Ulka N.,Podgorski Izabela,Heilbrun Lance K.,Lawhorn-Crews Jawana M.,Dobson Kimberlee C.,Boerner Julie,Stark Karri,Smith Daryn W.,Heath Elisabeth I.,Fontana Joseph A.,Shields Anthony F.

Funder

Department of Defense National Oncogenomics and Molecular Imaging Center

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer;European Journal of Pharmacology;2023-10

2. Overexpression of LncRNA SNHG1 Were Suitable for Oncolytic Adenoviruse H101 Therapy in Oral Squamous-Cell Carcinoma;OncoTargets and Therapy;2020-12

3. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review;Cancer Cell International;2020-08-26

4. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86);Clinical Cancer Research;2020-01-28

5. Design, Synthesis and Anticancer Activity Studies of Novel Trimethoxyphenyl-quinoline Derivatives;Chinese Journal of Organic Chemistry;2020